MJ Treur
22 Papers
103 Citations
MJ Treur is an academic researcher. The author has contributed to research in topics: Hepatitis C & Simeprevir. The author has an hindex of 7, co-authored 18 publications.
Chat about Author
Papers
Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
TL;DR: A unified Bayesian meta‐regression model suggests that a typical rFVIIa regimen will resolve joint bleeds more effectively than a typical aPCC regimen after 12, 24 and 36’h.
48
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
TL;DR: The model predicts that it is cost-effective to keep a patient with schizophrenia in Germany on branded risperidone instead of switching him/her to generic risperodone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5.2%.
34
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Roman Hájek,Jiri Jarkovsky,Vladimir Maisnar,Ludek Pour,Ivan Spicka,Jiri Minařík,Evžen Gregora,Petr Kessler,Michal Sýkora,Hana Fraňková,Marco Campioni,Lucy DeCosta,MJ Treur,Sebastian Gonzalez-McQuire,Walter Bouwmeester +14 more
TL;DR: Exploratory analyses revealed that younger age (≤ 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression‐free survival, especially in the early treatment lines.
22
A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service
TL;DR: Compared to other currently licensed treatment options, SMV’+ PR represents a cost effective treatment option for patients with chronic genotype 1 HCV infection, reflecting the QALY benefit of an increased likelihood of SVR with SMV, combined with lower overall drug costs, due to reduced mean treatment duration.
19
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan
TL;DR: SMV/PR is estimated to be the most cost-effective treatment strategy for treatment-naïve HCV genotype 1 patients in Japan.
15